The effect of FOXA2 rs1209523 on glucose-related phenotypes and risk of type 2 diabetes in Danish individuals

详细信息    查看全文

• 作者：Karina Banasik (1)
  Mette Hollensted (1)
  Ehm Andersson (1)
  Thomas Spars? (1)
  Annelli Sandb?k (2)
  Torsten Lauritzen (2)
  Torben J?rgensen (3) (4)
  Daniel R Witte (5)
  Oluf Pedersen (1) (3) (6) (7)
  Torben Hansen (1) (7) (8)
  
• 刊名：BMC Medical Genetics
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：13
• 期：1
• 全文大小：165KB
• 参考文献：1. Sund NJ, Vatamaniuk MZ, Casey M, Ang SL, Magnuson MA, Stoffers DA, Matschinsky FM, Kaestner KH: Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. / Genes Dev 2001,15(13):1706-715. CrossRef
  2. Zhu Q, Yamagata K, Yu L, Tomura H, Yamada S, Yang Q, Yoshiuchi I, Sumi S, Miyagawa J, Takeda J, Hanafusa T, Matsuzawa Y: Identification of missense mutations in the hepatocyte nuclear factor-3beta gene in Japanese subjects with late-onset Type II diabetes mellitus. / Diabetologia 2000,43(9):1197-200. CrossRef
  3. Navas MA, Vaisse C, Boger S, Heimesaat M, Kollee LA, Stoffel M: The human HNF-3 genes: cloning, partial sequence and mutation screening in patients with impaired glucose homeostasis. / Hum Hered 2000,50(6):370-81. CrossRef
  4. Tabassum R, Chavali S, Dwivedi OP, Tandon N, Bharadwaj D: Genetic variants of FOXA2: risk of type 2 diabetes and effect on metabolic traits in North Indians. / Journal of Human Genetics 2008,53(11-2):957-65. CrossRef
  5. Xing C, Cohen JC, Boerwinkle E: A weighted false discovery rate control procedure reveals alleles at FOXA2 that influence fasting glucose levels. / Am J Hum Genet 2010,86(3):440-46. CrossRef
  6. J?rgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C: A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. / Eur J Cardiovasc Prev Rehabil 2003,10(5):377-86. CrossRef
  7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. / Diabetologia 1985,28(7):412-19. CrossRef
  8. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Volund A, Borch-Johnsen K, Pedersen O: The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and glucose tolerance. / Diabetes Care 2007,30(2):257-62. CrossRef
  9. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. / Diabetes Care 1999,22(9):1462-470. CrossRef
  10. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Magi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JR, Egan JM, Lajunen T, / et al.: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. / Nat Genet 2010,42(2):105-16. CrossRef
  11. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Bostrom KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, / et al.: Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. / Nat Genet 2008,40(5):638-45. CrossRef
  12. Gao N, Le Lay J, Qin W, Doliba N, Schug J, Fox AJ, Smirnova O, Matschinsky FM, Kaestner KH: Foxa1 and Foxa2 maintain the metabolic and secretory features of the mature beta-cell. / Mol Endocrinol 2010,24(8):1594-604. CrossRef
  13. Clayton PT, Eaton S, ynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V, Malingre HE, Berger R, van dBI: Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. / JClinInvest 2001,108(3):457-65.
  14. Hornbak M, Banasik K, Justesen JM, Krarup NT, Sandholt CH, Andersson A, Sandbaek A, Lauritzen T, Pisinger C, Witte DR, Sorensen TA, Pedersen O, Hansen T: The minor C-allele of rs2014355 in ACADS is associated with reduced insulin release following an oral glucose load. / BMC Med Genet 2011, 12:4. CrossRef
  15. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/13/10/prepub
  
• 作者单位：Karina Banasik (1)
  Mette Hollensted (1)
  Ehm Andersson (1)
  Thomas Spars? (1)
  Annelli Sandb?k (2)
  Torsten Lauritzen (2)
  Torben J?rgensen (3) (4)
  Daniel R Witte (5)
  Oluf Pedersen (1) (3) (6) (7)
  Torben Hansen (1) (7) (8)
  
  1. The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
  2. Department of General Practice, University of Aarhus, Aarhus, Denmark
  3. Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
  4. Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
  5. Steno Diabetes Center, Gentofte, Denmark
  6. Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark
  7. Hagedorn Research Institute, Gentofte, Denmark
  8. Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
  
• ISSN：1471-2350

文摘

Background Variations within the FOXA family have been studied for a putative contribution to the risk of type 2 diabetes (T2D), and recently the minor T-allele of FOXA2 rs1209523 was reported to associate with decreased fasting plasma glucose levels in a study using a weighted false discovery rate control procedure to enhance the statistical power of genome wide association studies in detecting associations between low-frequency variants and a given trait. Thus, the primary aim of this study was to investigate whether the minor T-allele of rs1205923 in FOXA2 associated with 1) decreased fasting plasma glucose and 2) a lower risk of developing T2D. Secondly, we investigated whether rs1205923 in FOXA2 associated with other glucose-related phenotypes. Methods The variant was genotyped in Danish individuals from four different study populations using KASPar? PCR SNP genotyping system. We examined for associations of the FOXA2 genotype with fasting plasma glucose and estimates of insulin release and insulin sensitivity following an oral glucose tolerance test in 6,162 Danish individuals from the population-based Inter99 study while association with T2D risk was assessed in 10,196 Danish individuals including four different study populations. Results The FOXA2 rs1209523 was not associated with fasting plasma glucose (effect size (β) = -0.03 mmol/l (95%CI: -0.07; 0.01), p = 0.2) in glucose-tolerant individuals from the general Danish population. Furthermore, when employing a case-control setting the variant showed no association with T2D (odds ratio (OR) = 0.82 (95%CI: 0.62-1.07), p = 0.1) among Danish individuals. However, when we performed the analysis in a subset of 6,022 non-obese individuals (BMI < 30 kg/m2) an association with T2D was observed (OR = 0.68 (95%CI: 0.49-0.94), p = 0.02). Also, several indices of insulin release and β-cell function were associated with the minor T-allele of FOXA2 rs1209523 in non-obese individuals. Conclusions We failed to replicate association of the minor T-allele of FOXA2 rs1209523 with fasting plasma glucose in a population based sample of glucose tolerant individuals. More extensive studies are needed in order to fully elucidate the potential role of FOXA2 in glucose homeostasis.